Novavax is a clinical-stage vaccine company that develops recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization, seasonal quadrivalent influenza and pandemic H7N9 vaccines, a vaccine candidate against Ebola Virus and others. Founded in 1987, it is headquartered in Gaithersburg, Maryland.